Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01949311
Previous Study | Return to List | Next Study

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01949311
Recruitment Status : Active, not recruiting
First Posted : September 24, 2013
Last Update Posted : June 25, 2021
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Brief Summary:

The primary objective is to assess the long-term safety of dupilumab administered in adult participants with atopic dermatitis (AD).

The secondary objective of the study is to assess the immunogenicity of dupilumab in adult participants with AD, in the context of re-treatment, and to monitor efficacy parameters associated with long-term treatment.

Optional Sub-Study:

The primary objective of the sub-study is to assess the safety of the new dupilumab drug product in adult patients with AD after switching from the current dupilumab drug product.

The secondary objectives of the sub-study are to evaluate systemic exposure and immunogenicity of the new dupilumab drug product in adult patients with AD.


Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: Dupilumab Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2733 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials
Actual Study Start Date : October 10, 2013
Estimated Primary Completion Date : July 12, 2022
Estimated Study Completion Date : July 12, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema
Drug Information available for: Dupilumab

Arm Intervention/treatment
Experimental: Dupilumab
Participants will receive repeat doses of dupilumab
Drug: Dupilumab
Other Names:
  • DUPIXENT®
  • REGN668
  • SAR231893




Primary Outcome Measures :
  1. Number of Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to 5 Years ]
    The primary endpoint in the study is the incidence and rate (events per patient-year) of TEAEs through the last study visit.

  2. OPTIONAL SUB-STUDY: Incidence of Adverse Events of Special Interest (AESIs) through the last study visit after switching to the new dupilumab drug product [ Time Frame: Up to 24 Weeks ]

Secondary Outcome Measures :
  1. Number of Serious Adverse Events (SAEs) of special interest [ Time Frame: Up to 5 Years ]
    Incidence and rate (events per patient-year) of SAEs of special interest

  2. Number of AESIs [ Time Frame: Up to 5 Years ]
    Incidence and rate (events per patient-year) of AESIs

  3. Proportion of patients with Investigator's Global Assessment (IGA) score = 0-1 at each visit [ Time Frame: Up to 5 Years ]
    Proportion of patients who achieve and maintain a score of 0 to 1 on the IGA scale [(a 6-point scale ranging from 0 (clear) to 5 (very severe)]

  4. Proportion of patients with Eczema Area and Severity Index (EASI)-75 (≥75% reduction in EASI scores from baseline of the parent study) at each visit [ Time Frame: Up to 5 Years ]
  5. Proportion of patients with low disease activity state (eg, IGA ≤2) at each visit [ Time Frame: Up to 5 Years ]
  6. Change from baseline in EASI score at each visit [ Time Frame: Up to 5 Years ]
  7. Percent change from baseline in EASI score at each visit [ Time Frame: Up to 5 Years ]
  8. Proportion of patients with EASI-50 (≥50% reduction in EASI scores from baseline of the parent study) at each visit [ Time Frame: Up to 5 Years ]
  9. Proportion of patients with EASI-90 (≥90% reduction in EASI scores from baseline of the parent study) at each visit [ Time Frame: Up to 5 Years ]
  10. Change from baseline in Pruritus Numerical Rating Scale (NRS) [ Time Frame: Up to 5 Years ]
    The Pruritus NRS is a simple assessment tool that patients will use to report the average intensity of their pruritus (itch), during a 1-week recall period.

  11. Percent change from baseline in Pruritus NRS [ Time Frame: Up to 5 Years ]
    The Pruritus NRS is a simple assessment tool that patients will use to report the average intensity of their pruritus (itch), during a 1-week recall period.

  12. Proportion of patients with improvement (reduction) of Pruritus NRS ≥3 from baseline [ Time Frame: Up to 5 Years ]
  13. Proportion of patients with improvement (reduction) of Pruritus NRS ≥4 from baseline [ Time Frame: Up to 5 Years ]
  14. Proportion of patients requiring rescue treatment: Overall [ Time Frame: Up to 5 Years ]
  15. Proportion of patients requiring rescue treatment: Systemic treatment [ Time Frame: Up to 5 Years ]
  16. Proportion of patients requiring rescue treatment: Phototherapy [ Time Frame: Up to 5 Years ]
  17. Number of days on topical medication (per patient-year) [ Time Frame: Up to 5 Years ]
  18. Proportion of patients using topical medications over various periods during the study [ Time Frame: Up to 5 Years ]
  19. Changes from baseline to prespecified time points through the end of the study: Dermatology Life Quality Index (DLQI) [ Time Frame: Up to 5 Years ]
    The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL) (Badia 1999). The format is a simple response to 10 items, which assess QOL over the past week, with an overall scoring system of 0 to 30; a high score is indicative of a poor QOL.

  20. Changes from baseline to prespecified time points through the end of the study: Patient Oriented Eczema Measure (POEM) [ Time Frame: Up to 5 Years ]
    The POEM is a 7-item, validated questionnaire used in clinical practice and clinical trials to assess disease symptoms in children and adults (Charman 2004). The format is a response to 7 items (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) with a scoring system of 0 to 28; a high score is indicative of a poor QOL.

  21. Changes from baseline to prespecified time points through the end of the study: EuroQol-5D (EQ-5D) [ Time Frame: Up to 5 Years ]
    The EQ-5D as a measure of health-related QOL, defines health in terms of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 ordinal levels of severity: "no problem" (1), "some problems" (2), "severe problems" (3). Overall health state is defined as a 5-digit number.

  22. PK Parameter: Trough concentration (Ctrough) [ Time Frame: Up to 5 Years ]
  23. PK Parameter: Trough concentration at steady state (Ctrough, ss) [ Time Frame: Up to 5 Years ]
  24. PK Parameter: Last positive (quantifiable) concentration (Clast) [ Time Frame: Up to 5 Years ]
  25. PK Parameter: Time of the last positive (quantifiable) concentration (Tlast) [ Time Frame: Up to 5 Years ]
  26. OPTIONAL SUB-STUDY: Ctrough of functional dupilumab in serum before and after switching to the new dupilumab drug product [ Time Frame: Up to 24 Weeks ]
  27. OPTIONAL SUB-STUDY: Incidence of treatment-emergent anti-drug antibody (ADA) response in patients receiving the new dupilumab drug product [ Time Frame: Up to 24 Weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Participation in a prior clinical trial of dupilumab for AD and met one of the following:

    1. Received study treatment and adequately completed the assessments required for both the treatment and follow-up periods of the parent studies (except studies listed in b) as defined in the parent protocols
    2. Received study treatment in one the studies that have completed last patient, last visit irrespective of duration of participation, provided that patients completed with the instructions received during the study.
    3. Underwent screening in R668-AD-1334 (Liberty AD SOLO 1) or R668-AD-1416 (Liberty AD SOLO 2) but could not be randomized due to randomization closure.
  2. Willing and able to comply with all clinic visits and study-related procedures
  3. Able to understand and complete study-related questionnaires
  4. Provide signed informed consent

Optional Sub-Study:

  1. Provide separate informed consent
  2. Continuing in the treatment period of the main OLE study
  3. Demonstrated compliance with dupilumab therapy, as defined in the protocol

Key Exclusion Criteria:

  1. Patients who, during their participation in a previous dupilumab clinical trial, developed a serious adverse event (SAE) deemed related to dupilumab*, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with dupilumab may present an unreasonable risk for the patient.
  2. Patients who, during their participation in a previous dupilumab clinical trial, developed an AE that was deemed related to dupilumab* and led to study treatment discontinuation, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with dupilumab may present an unreasonable risk for the patient.
  3. Conditions in the previous dupilumab study consistent with protocol-defined criteria for permanent study drug discontinuation, if deemed related to dupilumab* or led to investigator - or sponsor-initiated withdrawal of patient from the study (eg, non-compliance, inability to complete study assessments, etc.).

    *Note for exclusion criteria # 1, 2, and 3: In studies that are still blinded, conditions deemed related to the study treatment will be considered related to dupilumab.

  4. Treatment with an investigational drug, other than dupilumab, within 8 weeks or within 5 half-lives (if known), whichever is longer, before the baseline visit
  5. Pregnant or breastfeeding women, or planning to become pregnant or breastfeed during the patient's participation in this study

Optional Sub-Study:

1. Patients who have already completed the end of treatment visit (ie, visit 44) for the main study R668-AD-1225

Note: Other Protocol Defined Inclusion / Exclusion Criteria Apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01949311


Locations
Show Show 434 study locations
Sponsors and Collaborators
Regeneron Pharmaceuticals
Sanofi
Investigators
Layout table for investigator information
Study Director: Clinical Trial Management Regeneron Pharmaceuticals
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01949311    
Other Study ID Numbers: R668-AD-1225
2013-001449-15 ( EudraCT Number )
First Posted: September 24, 2013    Key Record Dates
Last Update Posted: June 25, 2021
Last Verified: June 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases